| abstract |
(57) [Summary] The present invention relates to a compound of the general formula I [Wherein, R 1 and R 2 are the same or different, a hydrogen atom, C 1 -C 5 alkyl group or a halogen atom, more 3-7 membered in total together with the C atom of the chain ring; R 3 Is a C 1 -C 5 alkyl group or a partially or fully fluorinated C 1 -C 5 alkyl group; A is an optionally substituted monocyclic or bicyclic aromatic ring, an ester group —COOR 4 , An alkenyl group —CR 5 ＣＲCR 6 R 7 , an alkynyl group —C≡CR 5 , or a partially or fully fluorinated C 1 -C 5 alkyl group; B is a carbonyl group or a CH 2 — group and Ar is A ring system selected from the group of the sub-formulas (2-11), and furthermore when B of the general formula I represents a CH 2 group, Ar additionally represents a phenyl group of the sub-formula (12)] It is a system gestagen. This new compound shows a remarkably strong affinity for the gestagen receptor. The compounds can be used alone or in combination with estrogens in contraceptive preparations. It is also useful for treating endometriosis. The compounds together with estrogens can also be used in medicaments for the treatment of gynecological disorders, the treatment of premenstrual disorders and replacement therapy. Based on this androgenic effect, the compounds are useful for male fertility control, male HRT and hormonal therapy and the treatment of androgen-induced diseases. |